David H. Altreuter

Ensco (United States) — United States

Immunology and Microbiology · Life Sciences

5h-index867citations10works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(9), Immune Response and Inflammation(3), Monoclonal and Polyclonal Antibodies Research(3), Immune Cell Function and Interaction(3), T-cell and B-cell Immunology(2)

Publications10 total

1004 ABS001: a retention-optimized intratumoral immunotherapy eliciting robust innate and adaptive responses in HPV and non-HPV tumors
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract 1601: Anti-tumor effect of GAGomer-mediated intra-tumoral IL-2 expression following systemic administration
Cancer Research·2017
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Nature Nanotechnology·2016· 186 cited
Tolerogenic synthetic nanoparticles for the prevention of anti-drug antibodies against biologic therapies (TECH3P.936)
The Journal of Immunology·2015· 1 cited
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Proceedings of the National Academy of Sciences·2014· 421 citedOpen Access
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release
Vaccine·2014· 160 citedOpen Access
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release
DSpace@MIT (Massachusetts Institute of Technology)·2014· 2 citedOpen Access
Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates
Vaccine·2014· 81 citedOpen Access
Adjuvant-carrying targeted Synthetic Vaccine Particles ( <i>t</i> SVP™) augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release (75.3)
The Journal of Immunology·2012
Development and preclinical evaluation of SEL-068, a novel <i>targeted</i> Synthetic Vaccine Particle ( <i>t</i> SVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine (75.11)
The Journal of Immunology·2012· 16 cited

Frequent Co-authors

Takashi Kishimoto(7), Conlin P. O’Neil(6), Erica Browning(6), Lloyd Johnston(6), Petr O. Ilyinskii(5), Lynnelle A. Pittet(5), Robert A. LaMothe(4), Omid C. Farokhzad(4), Róbert Langer(4), Ulrich H. von Andrian(4), Roberto Maldonado(3), Joseph D. Ferrari(3), Pallavi N. Kolte(3), Aaron P. Griset(3), Fen-Ni Fu(2), Frank Alexis(2), Elena Tonti(2), Jinjun Shi(2), Pamela A. Basto(2), Matteo Iannacone(2)